

FAS Ligand, HEK, human recombinant (rHuFASL-HEK)

Catalog No: 97439 Lot No: XXXXX Source: HEEK293

Synonyms: Fas ligand (TNF superfamily, member 6), APT1LG1, FASL, TNFSF6, CD178, tumor necrosis factor (ligand)

superfamily member 6, Apoptosis antigen ligand, Fas antigen ligand, APTL, CD95-L

Background

The type II transmembrane protein FASLG is a member of the tumor necrosis factor (TNF) superfamily. A fas ligand/receptor interaction has a significant part in the regulation of the immune system and the advancement of cancer. FASLG is expressed on the activated T cell surface as a nondisulfidelinked homotrimer. FASLG binding to Fas/CD95/TNFRSF6 on a nearby cell prompts apoptosis in the Fas expressing cell. FASLG is released from the cell surface by metalloproteinases as a soluble molecule that stays trimeric and is able to bind with Fas, but its capability to activate apoptosis is radically reduced. In addition, FASLG binds to DcR3 - a soluble trap receptor with no signal transduction capabilities. Flawed Fas-mediated apoptosis causes oncogenesis in addition to drug resistance in existing tumors. Constitutive expression of FASLG in a variety of tumors enables their immune evasion. Both mouse and human FASLG are active on mouse and human cells.

Description

Recombinant Human FAS Ligand produced in HEK293 cells is a polypeptide chain containing 147 amino acids (134 – 281 aa). FASLG is fused to a 6 amino acid His-tag at the N-terminus and purified by proprietary chromatographic techniques.

Physical Appearance

Sterile filtered clear solution.

Formulation

The FASLG solution (0.6 mg/ml) contains 1xPBS.

Stability

The FASLG solution, although stable at 4° C for 1 week, should be stored below -18°C. Please prevent freeze thaw cycles.

Purity

Greater than 95.0% as determined by (a) Analysis by SEC-HPLC, (b) Analysis by SDS-PAGE.

Usage

This product is offered by Biomol for research purposes only. Not for diagnostic purposes or human use. It may not be resold or used to manufacture commercial products without written approval of Biomol GmbH.